hepg2 red fluc hepg2 cells expressing gpc 3  (Revvity)

Journal: EJNMMI Research

Article Title: Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma

doi: 10.1186/s13550-023-00980-9

Figure Lengend Snippet: Experimental schematic. At pre-specified times after subcapsular hepatic injection of human HepG2 cells, 11.1 MBq of 89 Zr-αGPC3 was injected via the tail vein. Four days after injection, whole-body PET and CT images were acquired. Animals were subsequently euthanized, and livers were assessed for tumors histologically

Article Snippet: HepG2-Red-FLuc (HepG2) cells expressing GPC-3 and Luciferase from PerkinElmer (Bioware, cat. no. BW134280, RRID:CVCL_5I98) were cultured, suspended in Matrigel (BD Biosciences) and injected into the subcapsular hepatic space.

Techniques: Injection

Journal: Nature Communications

Article Title: Atomically dispersed golds on degradable zero-valent copper nanocubes augment oxygen driven Fenton-like reaction for effective orthotopic tumor therapy

doi: 10.1038/s41467-022-35515-8

Figure Lengend Snippet: a The cytotoxicity study of Cu@SA, Au@SA, and Au/Cu 0 @SAnanocubes with HepG2-Red-FLuc liver cancer cells by using MTT assay through 100 ppm in Cu concentration. b Live (green color) and dead cells (red color) stained with fluorescent green dye (Calein-AM) and red dye (propidium iodide), respectively, for cancer cells treated with Cu@SA, Au@SA, and Au/Cu 0 @SA nanocubes (one representative data was shown from three independently repeated experiments). c The profiles of cells viability with different Au 0.02 Cu 0.98 @SA concentrations for 24 h incubation at 37 °C. d Flow cytometry analysis of HepG2-Red-FLuc cancer cells treated with Cu@SA, Au@SA, and Au/Cu 0 @SA nanocubes. All data were obtained in triplicate ( n = 3, the error bars represented mean ± SD). Source data are provided as a Source Data file.

Article Snippet: HepG2-Red-FLuc cells were obtained from PerkinElmer (Product No. BW134280).

Techniques: MTT Assay, Concentration Assay, Staining, Incubation, Flow Cytometry

Journal: Nature Communications

Article Title: Atomically dispersed golds on degradable zero-valent copper nanocubes augment oxygen driven Fenton-like reaction for effective orthotopic tumor therapy

doi: 10.1038/s41467-022-35515-8

Figure Lengend Snippet: a The morphology of Au 0.02 Cu 0.98 @SA nanocubes treated with or without HepG2-Red-FLuc cancer cells as a function of time. b Cu + release stained by CopperGreen dye showing green color as a function of time and the corresponding quantitative analysis. c H 2 O 2 generation stained by hydrogen peroxide assay kit showing green color as a function of time and the corresponding quantitative analysis. d •OH generation stained by APF dye showing green color as a function of time and the corresponding quantitative analysis. e Analysis of hemolysis in blood containing 2% red blood cells from Au 0.02 Cu 0.98 @SA nanocubes. Negative and positive controls were conducted by immersing red blood cells in PBS and water, respectively. f Cytotoxicity analysis of vascular endothelial cells treated with Au 0.02 Cu 0.98 @SA nanocubes. The scale bar is 100 μm in all fluorescence images. All data were obtained in triplicate ( n = 3, the error bars represented mean ± SD, and p -values were calculated by one-way ANOVA). Source data are provided as a Source Data file (one representative data was shown from three independently repeated experiments).

Article Snippet: HepG2-Red-FLuc cells were obtained from PerkinElmer (Product No. BW134280).

Techniques: Staining, H2O2 Assay, Fluorescence

Journal: Nature Communications

Article Title: Atomically dispersed golds on degradable zero-valent copper nanocubes augment oxygen driven Fenton-like reaction for effective orthotopic tumor therapy

doi: 10.1038/s41467-022-35515-8

Figure Lengend Snippet: a Histology morphology of each organ with PBS and Au 0.02 Cu 0.98 @SA nanocubes on post-injection day 7 was observed by H&E staining (scale bar, 200 µm). b The biodistribution was determined by Cu concentration collected from Au 0.02 Cu 0.98 @SA nanocubes through intravenous injection (the inset showing accumulation without liver, n = 3). c Antitumor efficacy of different nanocubes (Au@SA, Au 0.5 Cu 0.5 @SA, Cu@SA, and Au 0.02 Cu 0.98 @SA) in HepG2-Red-FLuc orthotopic liver tumor mice ( n = 3). Tumor growth was monitored by the IVIS system. d The IVIS bioluminescence of livers with hepatocellular carcinoma in each treatment group after mice were sacrificed ( n = 3). e The expression of phospho-histone H2A.X (Ser139) and cleaved caspase-3 (Asp175) within hepatocellular carcinoma from each treatment group mice by IHC staining (scale bar, 100 µm). Experiments of H&E staining and IHC staining were repeated at least three times independently with similar tendencies and the result from a representative experiment was shown. The error bars represented mean ± SEM ( b–d ). The p -value was calculated by one-way ANOVA.

Article Snippet: HepG2-Red-FLuc cells were obtained from PerkinElmer (Product No. BW134280).

Techniques: Injection, Staining, Concentration Assay, Expressing, Immunohistochemistry

Journal: Experimental & Molecular Medicine

Article Title: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging

doi: 10.1038/s12276-019-0274-7

Figure Lengend Snippet: Half-maximal inhibitory concentration (IC 50 ) of apatinib and sorafenib in hepatocellular carcinoma cell lines

Article Snippet: The HepG2-Red-fLuc cell line was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: Concentration Assay

Journal: Experimental & Molecular Medicine

Article Title: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging

doi: 10.1038/s12276-019-0274-7

Figure Lengend Snippet: a HepG2-Red-fLuc and ( b ) SMMC-7721-fLuc cell-derived tumor-bearing mice on days 0, 6, 12, and 18 post-drug treatment. Changes in BLI signal intensity, tumor volume, and mouse body weight in mice bearing HepG2-Red-fLuc ( c, e, g ) and SMMC-7721-fLuc ( d, f, h ) cell xenograft tumors were evaluated. (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 vs. the control group

Article Snippet: The HepG2-Red-fLuc cell line was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: Derivative Assay, Control

Journal: Experimental & Molecular Medicine

Article Title: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging

doi: 10.1038/s12276-019-0274-7

Figure Lengend Snippet: a BLI signals of orthotopic HepG2-Red-fLuc cell-derived tumor-bearing mice on days 0, 3, 6, 9, 12, 15, and 18 post-drug treatment. b BLI signal intensity of mice. (*) P < 0.05, (**) P < 0.01 vs. the control group. c Body weight of mice. (*) P < 0.05, day 6 vs. day 0 in the sorafenib group. d The 3D BLT reconstruction in the control and sorafenib and apatinib treatment groups on day 20 post-drug treatment

Article Snippet: The HepG2-Red-fLuc cell line was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: Derivative Assay, Control